Targeting of Interferon-Beta to Produce a Specific, Multi-Mechanistic Oncolytic Vaccinia Virus
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Oncolytic viruses hold much promise for clinical treatment of many cancers, but a lack of systemic delivery and insufficient tumor cell killing have limited their usefulness. We have previously demonstrated that vaccinia virus strains are capable of systemic delivery to tumors in mouse models, but infection of normal tissues remains an issue. We hypothesized that interferon-beta (IFN-beta) expression from an oncolytic vaccinia strain incapable of responding to this cytokine would have dual benefits as a cancer therapeutic: increased anticancer effects and enhanced virus inactivation in normal tissues. We report the construction and preclinical testing of this virus. METHODS AND FINDINGS: In vitro screening of viral strains by cytotoxicity and replication assay was coupled to cellular characterization by phospho-flow cytometry in order to select a novel oncolytic vaccinia virus. This virus was then examined in vivo in mouse models by non-invasive imaging techniques. A vaccinia B18R deletion mutant was selected as the backbone for IFN-beta expression, because the B18R gene product neutralizes secreted type-I IFNs. The oncolytic B18R deletion mutant demonstrated IFN-dependent cancer selectivity and efficacy in vitro, and tumor targeting and efficacy in mouse models in vivo. Both tumor cells and tumor-associated vascular endothelial cells were targeted. Complete tumor responses in preclinical models were accompanied by immune-mediated protection against tumor rechallenge. Cancer selectivity was also demonstrated in primary human tumor explant tissues and adjacent normal tissues. The IFN-beta gene was then cloned into the thymidine kinase (TK) region of this virus to create JX-795 (TK-/B18R-/IFN-beta+). JX-795 had superior tumor selectivity and systemic intravenous efficacy when compared with the TK-/B18R- control or wild-type vaccinia in preclinical models. CONCLUSIONS: By combining IFN-dependent cancer selectivity with IFN-beta expression to optimize both anticancer effects and normal tissue antiviral effects, we were able to achieve, to our knowledge for the first time, tumor-specific replication, IFN-beta gene expression, and efficacy following systemic delivery in preclinical models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., & Coen, D. M. (1991) · Science · doi:10.1126/science.1851332 · Cited by 1,050
Stojdl, D. F., Lichty, B. D., tenOever, B. R., Paterson, J. M., Power, A. T., Knowles, S., Marius, R., Reynard, J., Poliquin, L., Atkins, H., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00241-1 · Cited by 842
Self-citationStojdl, D. F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., & Bell, J. C. (2000) · Nature Medicine · doi:10.1038/77558 · Cited by 815 · cited 1×
“In addition, a variety of unmodified small RNA viruses have demonstrated natural tumor tropism mediated by their inherent sensitivity to the interferon-mediated antiviral state in normal cells [4,8,9].”
BackgroundSelf-citationRecent progress in the battle between oncolytic viruses and tumours
Parato, K. A., Senger, D., Forsyth, P. A. J., & Bell, J. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1750 · Cited by 536 · cited 1×
“Oncolytic viruses hold promise for the treatment of cancer, but improvements are needed [”
BackgroundSelf-citationKirn, D., Martuza, R. L., & Zwiebel, J. (2001) · Nature Medicine · doi:10.1038/89901 · Cited by 502 · cited 1×
“Oncolytic viruses have promise as cancer therapeutics due to their targeted nature and ability to destroy cancer cells through novel mechanisms-of-action (oncolysis and/or necrosis) [”
BackgroundSelf-citationSymons, J. A., Alcamí, A., & Smith, G. L. (1995) · Cell · doi:10.1016/0092-8674(95)90076-4 · Cited by 490 · cited 1×
“]. Of particular importance, vaccinia expresses a secreted inhibitor of type-I IFN designated B18R [”
BackgroundClinical trial results with oncolytic virotherapy: a century of promise, a decade of progress
Liu, T.-C., Galanis, E., & Kirn, D. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0736 · Cited by 450 · cited 1×
“Oncolytic viruses can further be engineered to express therapeutic transgene products that can destroy tumors through diverse and complementary mechanisms [10,11].”
BackgroundSelf-citationCompact, Synthetic, Vaccinia Virus Early/Late Promoter for Protein Expression
Chakrabarti, S., Sisler, J. R., & Moss, B. (1997) · BioTechniques · doi:10.2144/97236st07 · Cited by 389 · cited 1×
“5 early/late promoter driving gene expression [26].”
McCart, J. A., Ward, J. M., Lee, J., Hu, Y., Alexander, H. R., Libutti, S. K., Moss, B., & Bartlett, D. L. (2001) · PubMed · Cited by 366
Biron, C. A. (1998) · Seminars in Immunology · doi:10.1006/smim.1998.0138 · Cited by 341 · cited 1×
“We hypothesized that expression of IFN-β from an oncolytic virus would have dual benefits by increasing anticancer efficacy and increasing safety. Although IFN-β in normal tissues inhibits viral replication [”
BackgroundKim, J. H., Oh, J. Y., Park, B. H., Lee, D. E., Kim, J. S., Park, H. E., Roh, M. S., Je, J. E., Yoon, J. H., Thorne, S. H., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.008 · Cited by 303 · cited 1×
“First, intravenous delivery of vaccinia viruses appears to be feasible in immunocompetent animal tumor models [29,30].”
BackgroundSelf-citationAlcamı́, A., Symons, J. A., & Smith, G. L. (2000) · Journal of Virology · doi:10.1128/jvi.74.23.11230-11239.2000 · Cited by 273 · cited 4×
“Of particular importance, vaccinia expresses a secreted inhibitor of type-I IFN designated B18R [21,22].”
BackgroundMethodInfluentialSmith, G. L., Symons, J. A., Khanna, A., Vanderplasschen, A., & Alcami, A. (1997) · Immunological Reviews · doi:10.1111/j.1600-065x.1997.tb01012.x · Cited by 239
Hermiston, T. W., & Kuhn, I. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700542 · Cited by 148 · cited 2×
“Transgene ‘‘arming’’ of oncolytic viruses has frequently been utilized to enhance antitumoral efficacy and for noninvasive imaging purposes [10].”
BackgroundDong, Z., Greene, G. L., Pettaway, C. A., Dinney, C. P., Eue, I., Lu, W., BUCANA, C. D., Balbay, M. D., Bielenberg, D. R., & Fidler, I. J. (1999) · PubMed · Cited by 146
RNA viruses as virotherapy agents
Russell, S. J. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700535 · Cited by 146 · cited 1×
“In addition, a variety of unmodified small RNA viruses have demonstrated natural tumor tropism mediated by their inherent sensitivity to the interferon-mediated antiviral state in normal cells [4,8,9].”
BackgroundSalazar, A. Μ., Levy, H. B., Ondra, S., Kende, M., Scherokman, B., Brown, D. S., Mena, H., Martin, N. S., Schwab, K. A., Donovan, D., et al. (1996) · Neurosurgery · doi:10.1227/00006123-199606000-00006 · Cited by 129
Reovirus as a novel oncolytic agent
Norman, K. L., & Lee, P. W. K. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9871 · Cited by 124 · cited 1×
“In addition, a variety of unmodified small RNA viruses have demonstrated natural tumor tropism mediated by their inherent sensitivity to the interferon-mediated antiviral state in normal cells [4,8,9].”
BackgroundBioluminescence imaging of vaccinia virus: Effects of interferon on viral replication and spread
Luker, K. E., Hutchens, M. A., Schultz, T. L., Pekosz, A. S., & Luker, G. D. (2005) · Virology · doi:10.1016/j.virol.2005.06.049 · Cited by 115 · cited 1×
“Direct correlation between in vivo bioluminescence from luciferase-expressing vaccinia and viral replication in different tissues has been demonstrated previously [27].”
BackgroundEvasion of innate immunity by vaccinia virus
Haga, I. R., & Bowie, A. (2005) · Parasitology · doi:10.1017/s0031182005008127 · Cited by 101 · cited 4×
“In addition, additional proteins are expressed that may prevent infected cells from responding to IFN by blocking STAT1 signaling (H1L) [20].”
BackgroundInfluentiallnterferon‐β gene therapy for cancer: Basic research to clinical application
Yoshida, J., Mizuno, M., & Wakabayashi, T. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02194.x · Cited by 90
Tumor vascular targeting therapy with viral vectors
Liu, Y., & Deisseroth, A. (2005) · Blood · doi:10.1182/blood-2005-10-4114 · Cited by 88 · cited 1×
“Endothelial cells are attractive targets for oncolytic viruses, given their accessibility to infection by intravascular virus [32].”
BackgroundRas-dependent oncolysis with an adenovirus VAI mutant.
Cascalló, M., Capellá, G., Mazo, A., & Alemany, R. (2003) · PubMed · Cited by 88
Characteristics of tumor-associated endothelial cells derived from glioblastoma multiforme
Charalambous, C., Chen, T. C., & Hofman, F. M. (2006) · Neurosurgical Focus · doi:10.3171/foc.2006.20.4.e22 · Cited by 69 · cited 1×
“]. Tumor-associated endothelial cells may be specifically susceptible to this vaccinia mutant for several reasons [”
BackgroundShashkova, E. V., Spencer, J. F., Wold, W. S. M., & Doronin, K. (2006) · Molecular Therapy · doi:10.1038/sj.mt.6300064 · Cited by 68
Oncolytic Virotherapy: Approaches to Tumor Targeting and Enhancing Antitumor Effects
Thorne, S. H., Hermiston, T. W., & Kirn, D. H. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.09.007 · Cited by 64
Self-citationTada, H., Maron, D. J., Choi, E. A., Barsoum, J., Lei, H., Xie, Q. M., Liu, W., Ellis, L. M., Moscioni, A. D., Tazelaar, J., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9841 · Cited by 61 · cited 1×
“]. However, previous approaches have suffered from a lack of targeted gene delivery [”
BackgroundDirect Evidence That IFN- β Functions as a Tumor-Suppressor Protein
Kaynor, C., Xin, M., Wakefield, J., Barsoum, J., & Qin, X.-Q. (2002) · Journal of Interferon & Cytokine Research · doi:10.1089/10799900260442511 · Cited by 49
Johnston, J. B., Nazarian, S. H., Natale, R., & McFadden, G. (2004) · Virology · doi:10.1016/j.virol.2004.11.030 · Cited by 44 · cited 1×
“Primary cells (NHBEs) were found to up-regulate IFN-b secretion in response to either MV infection (which has previously been demonstrated to produce IFN-b upon infection of human fibroblasts, probably through PKR activation [24]) or following exposure to LPS (which, along with viral glycolipids, binds to and activate…”
BackgroundStrategies to achieve systemic delivery of therapeutic cells and microbes to tumors
Thorne, S. H. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.1.41 · Cited by 28 · cited 1×
“]. In particular, systemic efficacy against metastatic tumors will be required in order to have a major impact on cancer patient survival. Novel approaches are therefore needed to improve intravenous safety and efficacy [”
BackgroundSelf-citationBrown, J. L., Barsoum, J., & Qin, X.-Q. (2002) · Journal of Interferon & Cytokine Research · doi:10.1089/10799900260100222 · Cited by 27
Interferon-β and neuroprotection in multiple sclerosis—Facts, hopes and phantasies
Kieseier, B. C., & Hartung, H. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.09.007 · Cited by 22
Joffe, J., Perren, T. J., Bradley, C., Primrose, J. M., Hallam, S., Ward, U., Illingworth, J. M., & Selby, P. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.69 · Cited by 6 · cited 1×
“Antitumoral efficacy was reported, however, both in patients with brain tumors (including glioblastoma multiforme) [34,35] and in a patient with colorectal carcinoma [36].”
Background
Cited by
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Going viral with cancer immunotherapy
Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3770 · Cited by 581
Self-citationPark, B.-H., Hwang, T., Liu, T.-C., Sze, D. Y., Kim, J.-S., Kwon, H.-C., Oh, S. Y., Han, S.-Y., Yoon, J.-H., Hong, S.-H., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70107-4 · Cited by 521
Self-citationTargeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
Kirn, D. H., & Thorne, S. H. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2545 · Cited by 402
Self-citationVaccinia virus immune evasion: mechanisms, virulence and immunogenicity
Smith, G. L., Benfield, C. T. O., Maluquer de Motes, C., Mazzon, M., Ember, S. W. J., Ferguson, B. J., & Sumner, R. P. (2013) · Journal of General Virology · doi:10.1099/vir.0.055921-0 · Cited by 364
Metadata
- Authors
- Kirn, D. H., Wang, Y., Le Boeuf, F., Bell, J., & Thorne, S. H.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-12-27
- Volume
- 4
- Issue
- 12
- Pages
- e353
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2058025467
- Cited by
- 203
- References
- 33
- FWCI
- 6.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.